Coupling interferon to a synthetic PEG molecule could increase the therapeutic’s dosing schedule from every other day to every one to two weeks, according to researchers who believe the technology has blockbuster potential.
Modigene says that data from a trial of a Schering-Plough's (SP)
fertility stimulation hormone (FSH-CTP) confirms that carboxyl
terminal peptide (CTP) modification can extend the therapeutic
duration of protein drugs.
BioPartners has failed to bring its second biosimilar product into
Europe after the European Agency for the Evaluation of Medicinal
Products (EMEA) issued a negative opinion on its hepatitis C drug,
citing characterisation, manufacturing...
The interest in Syntonix' SynFusion and Transceptor technologies
intensified as Boehringer Ingelheim became the second
pharmaceutical company to use this technology to optimise its
therapeutic peptides for inhalation.
Serono of Switzerland is planning to expand its billion dollar
multiple sclerosis franchise with a new version of interferon beta
that would do away with the need for injections, reports Phil
Taylor.
BioPartners, currently leading the line amongst companies trying to
bring copies of off-patent biologic drugs to the European market,
has licensed a needle-free delivery technology for its human growth
hormone (hGH) product.
US firm Bolder BioTechnology has been awarded a patent for a new
technology that allows therapeutic proteins to be modified
chemically to improve its activity in the body.
Swiss biopharmaceuticals company BioPartners has filed its first
application in Europe for a generic version of interferon alpha, a
biological drug. If approved, the 'biosimilar' could be on the
market as early as next year.
Schering-Plough is to cut 18 per cent of its workforce at a
manufacturing plant in Brinny, Ireland, in the face of stiff
competition to two of the firm's biologic drugs.
The Intraject needle-free injector technology originated by
now-defunct UK company Weston Medical has passed a new series of
feasibility testing at new owner Aradigm.